OABI

OmniAb, Inc.

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OmniAb, Inc. (OABI) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) B (3.2) B (3.3) A (4.4) C+ (2.6) B (3.3)
2026-11-06 B- (2.9) B (3.3) B (3.3) A+ (4.5) C+ (2.7) B (3.3)
2026-10-30 B- (2.9) B (3.4) B (3.3) A+ (5.0) C+ (2.7) B (3.4)
2026-10-23 B- (2.9) B (3.3) B (3.3) A+ (5.0) C+ (2.6) B (3.4)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe